Investigational and Unproven Therapies in Atopic Dermatitis (Q37776588)

23 August 2017

1 reference

title

Investigational and unproven therapies in atopic dermatitis (English)

1 reference

23 August 2017

Investigational and Unproven Therapies in Atopic Dermatitis (English)

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

13 June 2024

main subject

allergen immunotherapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20670823

13 June 2024

Mark Boguniewicz

1 reference

23 August 2017

Peck Y. Ong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20670823

13 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20670823

13 June 2024

publication date

8 July 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0889856110000408?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

https://api.elsevier.com/content/article/PII:S0889856110000408?httpAccept=text/plain

13 June 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Immunology and Allergy Clinics of North America

13 June 2024

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

425-439

1 reference

Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Stress in mothers of young children with eczema

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

The course of life of patients with childhood atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Cost of atopic dermatitis and eczema in the United States

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Epidermal barrier dysfunction in atopic dermatitis.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

New insights into atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Recent insights into atopic dermatitis and implications for management of infectious complications

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Topical corticosteroid phobia in patients with atopic eczema

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Patient perspectives on the management of atopic dermatitis.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Emerging drugs for atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Management of atopic dermatitis using photo(chemo)therapy

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

A multidisciplinary approach to evaluation and treatment of atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm)

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Loss-of-Function Mutations in the Filaggrin Gene Lead to Reduced Level of Natural Moisturizing Factor in the Stratum Corneum

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Bioactive molecules from the Blue Lagoon: in vitro and in vivo assessment of silica mud and microalgae extracts for their effects on skin barrier function and prevention of skin ageing

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Silver-loaded seaweed-based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single-blinded exploratory in vivo study

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Antiseptic efficacy of a low-dosed topical triclosan/chlorhexidine combination therapy in atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

A randomized double-blind controlled trial to compare a triclosan-containing emollient with vehicle for the treatment of atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Infection control by antibody disruption of bacterial quorum sensing signaling

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Targeted immunotherapy for staphylococcal infections : focus on anti-MSCRAMM antibodies

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Vaccine assembly from surface proteins of Staphylococcus aureus.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Severe eczema vaccinatum in a household contact of a smallpox vaccinee

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Antiviral activity of human beta-defensin 3 against vaccinia virus

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Antibacterial properties of cationic steroid antibiotics

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Synthesis and characterization of peptide-cationic steroid antibiotic conjugates

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Ceragenins: a class of antiviral compounds to treat orthopox infections.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Chemokine receptors in T-cell-mediated diseases of the skin

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Down-regulation of atopic dermatitis-associated serum chemokines by wet-wrap treatment: a pilot study

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Novel CC chemokine receptor 4 antagonist RS-1154 inhibits ovalbumin-induced ear swelling in mice

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Small molecule antagonists for chemokine CCR3 receptors

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

A therapeutic effect of STAT6 decoy oligodeoxynucleotide ointment in atopic dermatitis: a pilot study in adults

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Topical suplatast tosilate (IPD) ameliorates Th2 cytokine-mediated dermatitis in caspase-1 transgenic mice by downregulating interleukin-4 and interleukin-5

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Suplatast/tacrolimus combination therapy for refractory facial erythema in adult patients with atopic dermatitis: a meta-analysis study

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Efficacy of anti-IgE therapy in patients with atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Failure of omalizumab for treatment of severe adult atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Treatment of recalcitrant atopic dermatitis with omalizumab

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Topical vitamin D3 downregulates IgE-mediated murine biphasic cutaneous reactions

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Heliotherapy improves vitamin D balance and atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Heliotherapy in atopic dermatitis: a prospective study on climatotherapy using the SCORAD index

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Endogenous antimicrobial peptides and skin infections in atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Contrasting disease patterns in psoriasis and atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Administration of oral vitamin D induces cathelicidin production in atopic individuals

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Effect of a Mycobacterium vaccae derivative on paediatric atopic dermatitis: a randomized, controlled trial

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Effect of Mycobacterium vaccae on atopic dermatitis in children of different ages

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Treatment of pruritus with topically applied opiate receptor antagonist

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

IL-31: a new link between T cells and pruritus in atopic skin inflammation

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Decreased production of semaphorin 3A in the lesional skin of atopic dermatitis

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming.

13 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IAC.2010.05.002

13 June 2024

Identifiers

1 reference

23 August 2017

1 reference